Icatibant Injection
For Hereditary Angioedema (HAE) Patients
Generic Icatibant Injection is an FDA-approved, fully substitutable, chemically equivalent,* and affordable option when treating acute attacks of HAE.
Icatibant Injection is a bradykinin B2 receptor antagonist indicated for treatment of acute attacks of Hereditary angioedema (HAE) in adults 18 years of age and older. It is not known if Icatibant Injection is safe or effective for children under 18 years of age.
*Fresenius Kabi’s Icatibant Injection is fully substitutable and chemically equivalent to Firazyr®.
On-Demand Treatment
for HAE Attacks
Icatibant Injection can be used to treat all acute HAE attacks, including cutaneous, abdominal, and laryngeal attacks. It can reduce the duration and time to resolution of the attack.
Brand-Name
vs. Generic
Icatibant Injection, manufactured by Fresenius Kabi, is less expensive, easy to use, and made with the same quality ingredients as the brand-name product.
A Trustworthy,
Reliable Source
Fresenius Kabi is a leading provider of generic medications with a 100-year history of delivering innovative therapies that are safe, efficient, and affordable.
Help Your Patients Be Prepared
The World Allergy Organization and the European Academy of Allergy and Clinical Immunology recommend patients be ready to manage their disease by keeping two on-demand HAE treatments with them at all times.
